Website News and Research

RSS

Fingolimod offers minor added benefit for patients with RRMS

The immunosuppressive drug fingolimod (trade name: Gilenya-) is approved for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in adults. In an early benefit assessment pursuant to "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) assessed whether fingolimod offers an added benefit compared with the present standard therapy.

6 Jul 2012

Geological Society of London, Elsevier win 2012 Getenergy award

Elsevier, a world-leading provider of scientific, medical and technical information products and services, today announced that, together with the Geological Society of London, it has won the award for best Education/Industry Partnership at the 2012 Getenergy awards ceremony.

4 Jul 2012

Signs that a child is seriously ill: Interview with Professor Middleton

There are several signs that indicate that a child is seriously ill. These can be spotted by parents, teachers and carers as well as by me or any other doctor or nurse.

4 Jul 2012

Cuban company's sales of larvicides to fight malaria-carrying mosquitoes in Africa continue despite U.N. concern, Miami Herald reports

The Cuban state-owned company Labiofam "is increasing sales of its mosquito larvicides to fight malaria in Africa, despite cautions by U.N. experts that such products have limited use and are not the most cost-effective method of attacking the disease," the Miami Herald reports.

4 Jul 2012

Hearing loss linked to Alzheimer's, heart disease, chronic kidney diseases and diabetes

Ear plug retailer, All Ear Plugs, urges Brits to take more care in protecting their ears following the release of data from the Better Hearing Institute (BHI) in the US linking hearing loss to chronic diseases.

2 Jul 2012

HIV therapy: Interview with Joël Crouzet, CEO of InnaVirVax

HIV therapy has traditionally been associated with antiretrovirals, which considerably reduce the amount of virus present in the blood to nearly undetectable levels.

29 Jun 2012

New laboratory model for Huntington's disease

Cedars-Sinai scientists have joined with expert colleagues around the globe in using stem cells to develop a laboratory model for Huntington's disease, allowing researchers for the first time to test directly on human cells potential treatments for this fatal, inherited disorder.

29 Jun 2012

BFC develops new Fertility App

Well in short the answer is yes if you are trying to conceive! And in this day and age where the smart phone is consulted over every aspect of day to day life, why shouldn't you rely on app to manage your love life as well! The Fertility App has been developed by Barbados Fertility Centre (BFC), a JCI accredited centre of excellence for IVF treatment located in the Caribbean and is the first app of its kind produced by a health care provider.

28 Jun 2012

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Infinity Pharmaceuticals, Inc. today reported preclinical data for IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data demonstrate potent PI3K-delta and -gamma inhibition in biochemical, cellular and whole blood assays and activity in multiple preclinical models of inflammatory disease, including rheumatoid arthritis and asthma.

28 Jun 2012

Indoor tanning beds banned for minors

Rhode Island took a great step today to protect youth from the dangers of skin cancer by prohibiting the use of indoor tanning beds by minors under the age of 18 without parental consent. This important action is based on significant scientific evidence that indoor tanning is undeniably linked to increased risk of developing melanoma and other forms of skin cancer.

27 Jun 2012

MAARA invests £340,000 into vital asthma and allergy research

A charity operating Britain's longest-running pollen database is investing over £340,000 into vital asthma and allergy research at the University of Leicester.

27 Jun 2012

Top-line final data from Provectus’ PV-10 phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

27 Jun 2012

Key issues in conducting research using electronic clinical data

Researchers participate in the Electronic Data Methods (EDM) Forum to maximize shared experiences and learning for using electronic clinical data to improve medical care and making informed health decisions. A July supplement to Medical Care is a special 'EDM Forum' issue, highlights key issues researchers are facing, and innovative approaches that have been developed to build the infrastructure and conduct research using electronic clinical data.

26 Jun 2012

Targeted delivery of therapeutic gene can effectively treat Pompe disease

Gene therapy to replace the protein missing in Pompe disease can be effective if the patient's immune system does not react against the therapy. Targeted delivery of the gene to the liver, instead of throughout the body,suppresses the immune response, improving the therapeutic effect, according to an article published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc.

26 Jun 2012

Varian launches on-line X-ray product finder tool

Varian Medical Systems, X-Ray Products, has launched an on-line product finder tool giving customers the ability to quickly locate needed replacement X-ray tubes as well as flat panel detectors for digital imaging.

26 Jun 2012

Ozone exposure associated with cardiovascular ailments

Young, healthy adult volunteers exposed for two hours to ozone developed physiological changes associated with cardiovascular ailments, according to a small study reported in Circulation, an American Heart Association journal.

26 Jun 2012

NIH awards SeKON contract under CIO-SP3 restricted solicitation

SeKON Enterprise, Inc., a leader in enterprise business applications and management consulting, announced today that the National Institutes of Health (NIH) has awarded the company a contract under its Chief Information Officer - Solutions and Partners 3 (CIO-SP3) restricted solicitation.

25 Jun 2012

Ads take issue with health law

News outlets report on various ad campaigns designed to criticize the Democrats' health law.

22 Jun 2012

RPCI shares information on two new electronic platforms

Embracing the expanded possibilities of how people are receiving their information in a technological age, Roswell Park Cancer Institute (RPCI) is sharing information on two new electronic platforms: a digital edition of its Roswellness consumer magazine and a mobile website optimized for smartphone users.

22 Jun 2012

UNICEF, ICA Fellow partnership can help develop quality communication for children

Dafna Lemish, a Fellow of the International Communication Association, has partnered with UNICEF to help launch and develop a free resource package available for worldwide use for the creation of quality media for children.

21 Jun 2012